The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences will deliver seven presentations at ESGCT2026, covering updates on its Duchenne program and platform technologies including POLARIS-101, its next-generation engineered myotropic capsid.
The company is inviting attendees to review their press release and visit their posters to learn more about developments in Duchenne therapies and platform innovation.
View post on X Loading...
Solid Biosciences previously launched POLARIS-101, a next-generation muscle-tropic capsid aimed at advancing gene therapy for neuromuscular and cardiac conditions. The company also shared new research on POLARIS-101 and its INSPIRE DUCHENNE study at a major neuromuscular research event, according to an earlier update detailing data releases. These activities reflect Solid's ongoing focus on innovation in Duchenne therapies and gene delivery platforms.